Toumas-Shehata, Mariam
Price, David
Amin Basheti, Iman
Bosnic-Anticevich, Sinthia
Article History
Received: 18 December 2013
Revised: 11 June 2014
Accepted: 20 July 2014
First Online: 13 November 2014
Competing interests
: David Price has consultancy arrangements with BoehringerIngelheim, GlaxoSmithKline, Merck, Mundipharma, Novartis, Chiesi and Teva. He or his research team have received grants and support for research in respiratory disease from the following organisations in the past 5 years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, Cipla, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Pfizer, Chiesi and Teva. He has spoken for: AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Merck, Mundipharma, Pfizer and Teva. He has shares in AKL Ltd which produces phytopharmaceuticals. He is the sole owner of Research in Real Life Ltd. Sinthia Bosnic-Anticevich has no shares in any pharmaceutical companies. In the past 5 years, she has provided consulting on the topic of inhaler device use to Pharmaceutical Society of Australia and the Pharmacy Guild of Australia. She has received research funding from the Australian Commonwealth Government Department of Health and the Australian Research Council. She has consultancy agreements and honoraria for presentation with Mundipharma and Teva. The remaining authors declare no conflict of interest.